OMICS International Organises 3000+ Global Conferenceseries Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
For more Conferences visit



Dr. Bishoy El-Aarag has awarded PhD degree in the field of medical Biochemistry (Cancer Science and Therapy) through a scientific channel between Egypt (Menoufia University) and Japan (Okayama University). He works as a lecturer of Biochemistry at Faculty of Science, Menoufia University, Egypt.


Lung cancer is the leading cause of cancer-related mortality in the word and non-small cell lung cancer (NSCLC) is the most common form of lung cancer. Numerous evidences had shown that thalidomide has potential for the inhibition and therapy of cancer. The present study aimed to investigate the anti-tumor effect of novel two thalidomide dithiocarbamate analogs towards human lung cancer A549 cells. The anti-proliferative, apoptotic and migration effects of lung cancer cells induced by thalidomide analogs were examined. Also, A549 cells were studied in tumor xenograft model. Our results revealed that thalidomide analogs exhibited anti-proliferative and apoptotic effect more than thalidomide itself. Also, analogs 1 and 2 suppressed the expression levels of VEGF165 by 42% and 53.25% and MMP-2 by 45% and 52% respectively. Moreover, thalidomide analogs 1 and 2 showed potent anti-tumor activity in vivo as they reduced the tumor volume by 30.11% and 53.52% respectively while thalidomide recorded 10.3% compared to vehicle control. Taken together, our study improved that thalidomide dithiocarbamate analogs are more potent anti-tumor and anti-angiogenic agents with more pronounced effect than thalidomide itself.